Initiative, together with the Broad Institute of MIT and Harvard, aims to accelerate efforts to mine genetic data for insights into disease mechanisms.
Phase II trial to investigate Novo’s semaglutide and a combination of Gilead’s cilofexor and firsocostat, alone and in combination in cirrhosis due to NASH.